Blood-based CRC screening test identifies asymptomatic, low-grade tumors

Blood-based CRC screening test identifies asymptomatic, low-grade tumors

LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically meaningful performance among patients in an average risk screening population, according to a presentation.“Blood-based colorectal cancer screening holds potential to improve compliance with CRC screening recommendations given the the ability to seamlessly integrate a blood-based test into standard of care clinical pathways,” Hee Cheol Kim, MD, of the Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, South Korea, said during the ACGRead More

Share on facebook
Share on twitter
Share on linkedin